dcsimg

Information

Information

2019

Date Title
August 27, 2019 【News Releases】Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
June 18, 2019 【News Releases】HYPERCHOLESTEROLEMIA DRUG REPATHA® SC INJECTION RECEIVES SUPPLEMENTAL INDICATION APPROVAL AS MONOTHERAPY FOR TREATING HYPERCHOLESTEROLEMIA PATIENTS NOT SUITABLE FOR STATIN THERAPY
March 4, 2019 【News Releases】EVENITY® SUBCUTANEOUS INJECTION 105 mg SYRINGE LAUNCHED IN JAPAN FOR THE TREATMENT OF OSTEOPOROSIS WITH HIGH RISK OF FRACTURE
January 9, 2019 【News Releases】EVENITY® SUBCUTANEOUS INJECTION 105mg SYRINGE RECEIVES THE-FIRST-IN-THE-WORLD APPROVAL IN JAPAN FOR THE TREATMENT OF OSTEOPOROSIS AT HIGH RISK OF FRACTURE

2018

Date Title
November 27, 2018 【News Releases】BLINCYTO® for drip infusion 35 μg launched in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia
November 26, 2018 【News Releases】Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018
November 19, 2018 【News Releases】ERENUMAB PHASE 2 STUDY DEMONSTRATES SIGNIFICANT EFFICACY IN MIGRAINE PREVENTION IN JAPANESE PATIENTS
October 31, 2018 【News Releases】Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease
September 25, 2018 【News Releases】BLINCYTO® FOR DRIP INFUSION 35μg APPROVED IN JAPAN FOR THE TREATMENT OF RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
August 3, 2018 【News Releases】Application for Supplemental Indication Filed for Hypercholesterolemia Drug Repatha® SC Injection in Treating Statin-intolerant Patients
July 20, 2018 【News Releases】Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA
July 10, 2018 【News Releases】Hypercholesterolemia Drug Repatha® SC Injection The Repatha Cardiovascular Outcomes Study Results including Japanese Patients Have Been Updated in the Prescribing Information
May 17, 2018 【News Releases】FDA Approves Aimovig™ (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
April 17, 2018 【News Releases】Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment Failures
April 13, 2018 【News Releases】FDA APPROVES BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS AND CHILDREN
January 30, 2018 【News Releases】AMGEN REPORTS AIMOVIG™ (ERENUMAB) MET ALL PRIMARY AND SECONDARY ENDPOINTS IN UNIQUE PHASE 3B STUDY IN EPISODIC MIGRAINE PATIENTS WHO HAVE FAILED MULTIPLE PRIOR PREVENTIVE TREATMENTS
January 12, 2018 【News Releases】Repatha® SC Injection 420 mg Auto Mini Doser Launched in Japan

2017

Date Title
December 7, 2017 【News Releases】FDA Approves Amgen's Repatha® (evolocumab) To Prevent Heart Attack And Stroke
November 30, 2017 【News Releases】Erenumab Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention
November 13, 2017 【News Releases】NEW ANALYSES PRESENTED AT AHA 2017 SHOW REPATHA® (EVOLOCUMAB) SIGNIFICANTLY REDUCED CARDIOVASCULAR EVENTS IN PATIENTS WITH PERIPHERAL ARTERY DISEASE AND IN PATIENTS WITH A HISTORY OF HEART ATTACKS
October 20, 2017 【News Releases】CONSISTENT RESULTS OF JAPANESE POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN THE PHASE 3 STUDY OF ROMOSOZUMAB PRESENTED AT THE ANNUAL MEETING OF JAPAN OSTEOPOROSIS SOCIETY
September 15, 2017 【News Releases】New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes
September 11, 2017 【News Releases】Romosozumab ARCH Study Results Published In The New England Journal Of Medicine
September 7, 2017 【News Releases】New Data Demonstrate Aimovig™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies
August 30, 2017 【News Releases】Repatha® Receives Approval for New 420mg Single-Dose Delivery Option in Japan
August 29, 2017 【News Releases】New Virtual Histology Sub-Study Evaluates Impact Of Repatha® (Evolocumab) On Coronary Artery Plaque Composition
August 29, 2017 【News Releases】New Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With History Of Stroke
August 28, 2017 【News Releases】New Repatha® (evolocumab) Analysis Demonstrates Cardiovascular Outcomes Efficacy And Safety Of Achieving Very Low LDL-C Levels
August 16, 2017 【News Releases】Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine
August 7, 2017 【News Releases】PHASE 2 CLINICAL TRIAL OF OMECAMTIV MECARBIL IN JAPANESE PATIENTS WITH HEART FAILURE
July 27, 2017 【News Releases】FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
July 16, 2017 【News Releases】Amgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US
June 5, 2017 【News Releases】Amgen Submits Regulatory Applications For Repatha® (evolocumab) Cardiovascular Outcomes Data In US And Europe
June 3, 2017 【News Releases】Amgen Presents New Phase 2 Data On IMLYGIC® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017
June 1, 2017 【News Releases】AMGEN ASTELLAS BIOPHARMA APPOINTS STEVE SUGINO AS THE PRESIDENT AND REPRESENTATIVE DIRECTOR
May 31, 2017 【News Releases】REPATHA® (EVOLOCUMAB) REDUCED CARDIOVASCULAR EVENTS IN PATIENTS WITH BASELINE LDL-C LEVELS BELOW CURRENT TARGETS
May 24, 2017 【News Releases】Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of Romosozumab In Postmenopausal Women With Osteoporosis
April 18, 2017 【News Releases】AMGEN ASTELLAS BIOPHARMA NEW GENERAL MANAGER
April 1, 2017 【News Releases】Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With Romosozumab
March 18, 2017 【News Releases】LOWERING LDL LEVELS WITH REPATHA® (EVOLOCUMAB) DID NOT ADVERSELY AFFECT COGNITIVE FUNCTION IN LANDMARK PHASE 3 STUDY
March 17, 2017 【News Releases】LANDMARK OUTCOMES STUDY SHOWS THAT REPATHA® (EVOLOCUMAB) DECREASES LDL-C TO UNPRECEDENTED LOW LEVELS AND REDUCES RISK OF CARDIOVASCULAR EVENTS WITH NO NEW SAFETY ISSUES
March 14, 2017 【News Releases】REPATHA® (EVOLOCUMAB) FOUR-YEAR OPEN-LABEL FOLLOW-UP STUDY PUBLISHED IN JAMA CARDIOLOGY
March 13, 2017 【News Releases】REPATHA® (EVOLOCUMAB) DEMONSTRATES REDUCED NEED FOR APHERESIS IN PATIENTS WITH HIGH LDL CHOLESTEROL IN PHASE 3 STUDY
March 1, 2017 【News Releases】BLINCYTO® (BLINATUMOMAB) SIGNIFICANTLY IMPROVED OVERALL SURVIVAL IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA COMPARED TO CHEMOTHERAPY
February 2, 2017 【News Releases】AMGEN ANNOUNCES REPATHA® (EVOLOCUMAB) SIGNIFICANTLY REDUCED THE RISK OF CARDIOVASCULAR EVENTS IN FOURIER OUTCOMES STUDY

2016

Date Title
December 20, 2016 【News Releases】AMGEN ASTELLAS AND ASTELLAS ANNOUNCE SUBMISSION OF APPLICATION FOR INVESTIGATIONAL OSTEOPOROSIS MEDICATION ROMOSOZUMAB IN JAPAN
November 30, 2016 【News Releases】THE LANCET PUBLISHES RESULTS FROM COSMIC-HF TRIAL SHOWING OMECAMTIV MECARBIL SIGNIFICANTLY IMPROVED CARDIAC FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE
November 16, 2016 【News Releases】AMGEN ANNOUNCES ERENUMAB SIGNIFICANTLY REDUCES MONTHLY MIGRAINE DAYS IN PATIENTS WITH EPISODIC MIGRAINE IN SECOND PHASE 3 STUDY
November 15, 2016 【News Releases】REPATHA® (EVOLOCUMAB) REGRESSES ATHEROSCLEROSIS IN PATIENTS WITH CORONARY ARTERY DISEASE
November 12, 2016 【News Releases】RESULTS FROM PHASE 3 BRIDGE STUDY SHOW ROMOSOZUMAB SIGNIFICANTLY INCREASES BONE MINERAL DENSITY IN MEN WITH OSTEOPOROSIS
October 31, 2016 【News Releases】AMGEN HIGHLIGHTS REPATHA® (EVOLOCUMAB) GLAGOV IMAGING STUDY AMONGST DATA TO BE PRESENTED AT AHA SCIENTIFIC SESSIONS 2016
October 13, 2016 【News Releases】AMGEN ASTELLAS BIOPHARMA NEW GENERAL MANAGER
October 3, 2016 【News Releases】STUDY RESULTS PUBLISHED IN JOURNAL OF CLINICAL ONCOLOGY SHOW BLINCYTO® (BLINATUMOMAB) INDUCED COMPLETE REMISSION IN HEAVILY PRETREATED PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
September 28, 2016 【News Releases】AMGEN ANNOUNCES ERENUMAB SIGNIFICANTLY REDUCES MONTHLY MIGRAINE DAYS IN PATIENTS WITH EPISODIC MIGRAINE IN FIRST PHASE 3 STUDY
September 20, 2016 【News Releases】AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 GLAGOV IMAGING STUDY OF REPATHA® (EVOLOCUMAB)
September 18, 2016 【News Releases】RESULTS FROM PHASE 3 FRAME STUDY OF ROMOSOZUMAB SHOWED SIGNIFICANT REDUCTIONS IN BOTH NEW VERTEBRAL AND CLINICAL FRACTURES IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
September 15, 2016 【News Releases】AMGEN PRESENTS POSITIVE DATA AT EHMTIC 2016 DEMONSTRATING ERENUMAB SIGNIFICANTLY REDUCES MONTHLY MIGRAINE DAYS IN PATIENTS WITH CHRONIC MIGRAINE
September 7, 2016 【News Releases】AMGEN TO HIGHLIGHT ABSTRACTS ON OSTEOPOROSIS DISEASE STATE AND TREATMENT AT AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH ANNUAL MEETING
September 1, 2016 【News Releases】FDA APPROVES BLINCYTO® (BLINATUMOMAB) FOR USE IN PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
August 28, 2016 【News Releases】REPATHA® (EVOLOCUMAB) ANALYSES SHOW EFFICACY AND SAFETY ACROSS RISK GROUPS IN RESULTS PRESENTED AT ESC CONGRESS 2016
August 22, 2016 【News Releases】NEW DATA ADD TO UNDERSTANDING OF REPATHA® (EVOLOCUMAB) IN MULTIPLE PATIENT POPULATIONS
July 21, 2016 【News Releases】AMGEN AND UCB SUBMIT BIOLOGICS LICENSE APPLICATION FOR ROMOSOZUMAB TO THE FDA
June 10, 2016 【News Releases】BLINCYTO® (BLINATUMOMAB) IMPROVED OVERALL SURVIVAL IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
June 8, 2016 【News Releases】AMGEN ANNOUNCES ERENUMAB (AMG 334) SIGNIFICANTLY REDUCES PATIENTS’ MONTHLY MIGRAINE DAYS IN PHASE 2 STUDY FOR THE PREVENTION OF CHRONIC MIGRAINE
May 23, 2016 【News Releases】THE RESULTS FROM A ONE YEAR TREATMENT OF REPATHA PRESENTED AT THE ANNUAL MEETING OF THE JAPAN DIABETES SOCIETY (JDS 2016)
May 3, 2016 【News Releases】FDA GRANTS PRIORITY REVIEW FOR AMGEN’S SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR BLINCYTO® (BLINATUMOMAB)
April 21, 2016 【News Releases】AMGEN ASTELLAS BIOPHARMA AND ASTELLAS INTRODUCE REPATHA® (EVOLOCUMAB) FOR THE TREATMENT OF HIGH CHOLESTEROL
April 3, 2016 【News Releases】Positive efficacy and tolerability study of Repatha® (Evolocumab) in statin-intolerant patients published in Journal Of The American Medical Association
April 1, 2016 【News Releases】AMGEN AND UCB PRESENT POSITIVE DATA AT ENDO 2016 COMPARING ROMOSOZUMAB WITH TERIPARATIDE
March 22, 2016 【News Releases】Positive top-line results from phase 3 study evaluating ROMOSOZUMAB in men with osteoporosis
March 1, 2016 【News Releases】Amgen submits supplemental biologics license application for BLINCYTO® (BLINATUMOMAB)
February 23, 2016 【News Releases】Positive top-line results from the phase 3 study of ROMOSOZUMAB in postmenopausal women with osteoporosis
February 4, 2016 【News Releases】Amgen announces positive top-line results from Phase 3 GAUSS-3 trial of Repatha® (evolocumab) in statin-intolerant patients with high cholesterol
February 4, 2016 【News Releases】Phase 3 study of BLINCYTO® (blinatumomab) met primary endpoint of overall survival in patients with B-cell precursor acute lymphoblastic leukemia
January 22, 2016 【News Releases】Repatha® (Evolocumab) approved as first PCSK9 inhibitor in Japan for the treatment of high cholesterol

2015

Date Title
December 7, 2015 【News Releases】Amgen presents data from three trials evaluating BLINCYTO® (BLINATUMOMAB) in acute Lymphoblastic Leukemia at ASH 2015
December 1, 2015 【News Releases】European Commission Approves Amgen's BLINCYTO® (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
November 6, 2015 【News Releases】Amgen to highlight cardiovascular portfolio at American Heart Association Scientific sessions 2015
October 22, 2015 【News Releases】New exploratory analysis showed romosozumab increased estimated bone strength more than teriparatide
September 30, 2015 【News Releases】Amgen Announces Positive CHMP Opinion for BLINCYTO® (BLINATUMOMAB) for the treatment of adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia)
September 28, 2015 【News Releases】Notice of preparation for establishing a sales organization and announcement of personnel affairs
September 11, 2015 【News Releases】Amgen submits application to FDA for new delivery option for montly administration of REPATHA™ (EVOLOCUMAB)
August 27, 2015 【News Releases】FDA approves Amgen’s new cholesterol-lowering medication REPATHA™ (EVOLOCUMAB)
August 25, 2015 【News Releases】Amgen to present new long-term REPATHA™ (EVOLOCUMAB) data analysis at ESC Congress 2015
July 21, 2015 【News Releases】Critical Milestone for Patients With Uncontrolled Cholesterol who Require Additional Intensive LDL-C Reduction
July 16, 2015 【News Releases】Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia chromosome-positive b-cell Precursor Acute Lymphoblastic Leukemia
June 19, 2015 【News Releases】Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease
May 22, 2015 【News Releases】Amgen Receives Positive CHMP Opinion For Use Of Repatha™ (Evolocumab) For The Treatment Of High Cholesterol
April 1, 2015 【News Releases】Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (Evolocumab) In The New England Journal Of Medicine

2014

Date Title
December 8, 2014 【News Releases】Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
December 6, 2014 【News Releases】Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease
December 3, 2014 【News Releases】FDA Approves BLINCYTO™ (blinatumomab) Immunotherapy For The Treatment of Relapsed or Refractory B-Cell Precursor Acute Lumphoblastic Leukemia
November 24, 2014 【News Releases】Amgen Announces Termination of All Amgen-Sponsored Clinical Studies of Rilotumumab In Advance Gastric Cancer
November 18, 2014 【News Releases】Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels
November 10, 2014 【News Releases】FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab
November 6, 2014 【News Releases】Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014
October 9, 2014 【News Releases】Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia
October 1, 2014 【News Releases】The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol
September 22, 2014 【News Releases】Amgen Submits Biologics License Application for Investigational BiTE® Immunotherapy Blinatumomab
September 2, 2014 【News Releases】Amgen Submits Marketing Authorization Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The European Medicines Agency
August 28, 2014 【News Releases】Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol
August 28, 2014 【News Releases】Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA
June 1, 2014 【News Releases】New Detailed Phase 3 Data Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With A Rare And Serious Genetic Disorder That Causes High Cholesterol
May 13, 2014 【News Releases】Journal Of The American Medical Association Publishes Phase 3 LAPLACE-2 Study Showing Evolocumab Significantly Reduced LDL Cholesterol In Patients On Statins Regardless Of Statin Dose
March 30, 2014 【News Releases】Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol in Statin Intolerant Patients and in Patients on Statins
March 29, 2014 【News Releases】New Detailed Data From Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol by 55-66 Percent Compared to Placebo in Patients With High Cholesterol
March 24, 2014 【News Releases】Amgen Astellas Biopharma Announces Positive Results From Phase 2 YUKAWA Study of Evolocumab (AMG 145) in Japanese Patients With High Cholesterol

2013

Date Title
September 27, 2013 【News Releases】Amgen Astellas BioPharma Appoints Leadership Team, Prepares to Begin Operations
May 29, 2013 【News Releases】Amgen and Astellas Announce Japan Alliance